Not Satisfied With Your Current OCD Medication? This Investigational Medication May Help
Research Center: Baylor College of Medicine, Department of Psychiatry and Behavioral Sciences
Location: Jamail Specialty Center, 1977 Butler Blvd, Suite E4.400 Houston, TX
Lead Doctor: Dr. Wayne Goodman
IRB Committee: This study has been reviewed and approved by the Advarra Institutional Review Board
Obsessive compulsive disorder or OCD is oftentimes a debilitating condition in which an individual experiences unwanted and distressing thoughts or impulses, and feels the urge to do repetitive behaviors that can interfere with their daily functioning. Most often, currently available medications are not effective enough by themselves to control the symptoms.
A current study at the Baylor College of Medicine is looking into the safety and efficacy of a new medication for treating OCD, compared to a placebo. The investigational medication (or placebo) will be taken as a complementary treatment in people who are experiencing inadequate response to their current standard of care medication for OCD.
This study seeks men and women who have been diagnosed with OCD and are currently taking medication for OCD. There are two phases to this study. Participants are asked to attend up to 6 study visits at the research site over a 12-week period (phase 1), with the option to continue taking the medication for up to 48 additional weeks (phase 2). Participants receiving a placebo will be switched to the investigational medication after the first 12 weeks, if they decide to continue in the study. All participants will be compensated $75 for each visit, up to $,1080 for participating in this study.
- You may see an improvement in the management of your OCD symptoms.
- You will be compensated $75 for each visit, up to $1,080 for participating in this study.
- You will be helping to advance medical research aimed at improving OCD treatments in the future.
- If you decide to participate in the study and later feel that you no longer wish to be part of it, you may withdraw at any time.
- Your records relating to this study and any other information received will be kept strictly confidential, except as required by law.
- Qualified health professionals will monitor your health as it relates to the study.
Who Can Participate?
- Men and women aged 18-65 who have been diagnosed with OCD.
- Able to attend up to 6 study visits at the research site over approximately 12 weeks (possibly more if you’d like to continue past the first phase of the study).
- Are currently taking an SSRI (Prozac, Zoloft, Lexapro, Paxil, Luvox or Celexa), Anafranil (clomipramine), Effexor (venlafaxine) or Pristiq (desvenlafaxine)